Research
Hormonal
Network pharmacology analysis suggests that the synergistic mechanism of combined exercise and medication involves the IL1B-STAT3 inflammatory axis and SIRT1/CD36 lipid metabolism network.
This is a mechanistic hypothesis. It suggests that combining exercise and medication may work by reducing inflammation (IL1B-STAT3) and improving lipid metabolism (SIRT1/CD36).
ModerateSupportsMEDIUM confidence
Network pharmacology suggests that the IL1B-STAT3 inflammatory axis and SIRT1/CD36 lipid metabolism network may be central to the mechanisms.
Why this rating
Based on computational network pharmacology, not direct clinical measurement of these specific pathways in the RCTs.
Source
The Effects of Exercise Combined with Pharmacotherapy on Body Composition and Metabolic Parameters in Overweight/Obese Adults: A Meta-Analysis and Network Pharmacology Study
Tianhang Peng et al. · Diabetes Metabolic Syndrome and Obesity · 2026
DOI 10.2147/dmso.s590529
Meta-analysis · 18 studies
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Combining exercise with pharmacotherapy (specifically GLP-1 agonists or orlistat) significantly enhances weight loss, BMI reduction, and body fat percentage compared to exercise alone in overweight/obese adults.Good
- Combined exercise and pharmacotherapy significantly reduces systolic and diastolic blood pressure and triglycerides compared to exercise alone, but does not significantly improve fasting glucose, HDL, or LDL.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →